Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that ER negative status confers therapeutic sensitivity to Fulvestrant in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved fulvestrant for reimbursement as a treatment option for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer for disease progression on or after adjuvant anti-estrogen therapy in patients who are postmenopausal women.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease progression on or after adjuvant anti-oestrogen therapy.